Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors

References

• Reubi JC, Kvols L, Krenning E, Lamberts SWJ. Distribution of somatostantin receptors in normal and tumor tissue. Metabolism 1990;39:78–81
   PubMed Web of Science ®Google Scholar
• Volante M, Rosas R, Allìa E, et al. Somatostatin, cortistatin and their receptors in tumours. Mol Cell Endocrinol 2008;286:219–29
   PubMed Web of Science ®Google Scholar
• Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389–427
   PubMed Web of Science ®Google Scholar
• Olsen JO, Pozderac RV, Hinkle G, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med 1995;25:251–61
   PubMed Web of Science ®Google Scholar
• Shen H, Hu D, Du J, et al. Paclitaxel–octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice. Eur J Pharmacol 2008;601:23–9
   PubMed Web of Science ®Google Scholar
• Huang CM, Wu YT, Chen ST. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem Biol 2000;7:453–61
   PubMed Web of Science ®Google Scholar
• Zhang J, Jin W, Wang X, et al. A Novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. Mol Pharm 2010;7:1159–68
   PubMed Web of Science ®Google Scholar
• Smith-Jones PM, Bischof C, Leimer M, et al. DOTA-Lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999;140:5136–48
   PubMed Web of Science ®Google Scholar
• Virgolini I, Szilvasi I, Kurtaran A, et al. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998;39:1928–36
   PubMed Web of Science ®Google Scholar
• Banerjee S, Das T, Chakraborty S, et al. 177Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy. Nucl Med Biol 2004;31:753–9
   PubMed Web of Science ®Google Scholar
• Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002;235:179–92
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004–14
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:159–8
   PubMed Web of Science ®Google Scholar
• Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263–8
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci 2004;61:2549–59
   PubMed Web of Science ®Google Scholar
• Lin WJ, Chen YC, Lin CC, et al. Characterization of pegylated copolymeric micelles and in vivo pharmacokinetics and biodistribution studies. J Biomed Mater Res B Appl Biomater 2006;77:188–94
   PubMed Web of Science ®Google Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189–207
   PubMedGoogle Scholar
• Zheng N, Dai W, Du W, et al. A novel lanreotide-encoded micelle system targets paclitaxel to the tumors with overexpression of somatostatin receptors. Mol Pharm 2012;9:1175–88
   PubMed Web of Science ®Google Scholar
• Krishnadas A, Rubinstein I, Önyüksel H. Sterically stabilized phospholipids mixed micelles: in vitro evalution as a novel carrier for water-insoluble drugs. Pharm Res 2003;20:297–302
   PubMed Web of Science ®Google Scholar
• Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 2004;56:1273–89
   PubMed Web of Science ®Google Scholar
• Cesur H, Rubinstein I, Pai A, Önyüksel H. Self-associated indisulam in phospholipids-based nanomicelles: a potential nanomedicine for cancer. Nanomedicine 2009;5:178–83
   PubMed Web of Science ®Google Scholar
• Gao Z, Lukyanov AN, Singhal A, Torchilin VP. Diacyllipid-polymer micelles as nanocarriers for poorly soluble anticancer drugs. Nano Lett 2002;2:979–82
   Web of Science ®Google Scholar
• Tang N, Du G, Wang N, et al. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst 2007;99:1004–15
   PubMed Web of Science ®Google Scholar
• Xu B, Xu H, Li YQ, et al. Expression of somatostatin receptor subtype 2 in 12 tumor cell lines. Guangdong Med J 2006;27:324–26
   Google Scholar
• Watt HL, Kumar U. Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells. Cancer Cell Int 2006;6:5–23
   PubMed Web of Science ®Google Scholar
• Huang CM, Wu YT, Chen ST. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem Biol 2000;7:453–61
   PubMed Web of Science ®Google Scholar
• Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:111–16
   PubMed Web of Science ®Google Scholar
• Lee SH, Yoo SD, Lee KH. Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999;72:357–63
   Web of Science ®Google Scholar
• Guo W, Johnson JL, Khan S, et al. Paclitaxel quantication in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study. Anal Biochem 2005;336:213–20
   PubMed Web of Science ®Google Scholar
• Zeng F, Lee H, Allen C. Epidermal growth factor-conjugated poly(ethylene glycol)-block-poly(delta-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics. Bioconjug Chem 2006;17:399–409
   PubMed Web of Science ®Google Scholar
• Liang HF, Yang TF, Huang CT, et al. Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells. J Control Release 2005;105:213–25
   PubMed Web of Science ®Google Scholar
• Huh KM, Lee SC, Cho YW, et al. Hydrotropic polymer micelle system for delivery of paclitaxel. J Control Release 2005;101:59–68
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590–8
   PubMed Web of Science ®Google Scholar
• Kim SY, Lee YM, Baik DJ, Kang JS. Toxic characteristics of methoxy poly(ethylene glycol)/poly(ɛ-caprolactone) nanospheres: in vitro and in vivo studies in the normal mice. Biomaterials 2003;24:55–63
   PubMed Web of Science ®Google Scholar
• Zhang C, Qu G, Sun Y, et al. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials 2008;29:1233–41
   PubMed Web of Science ®Google Scholar
• Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454–7
   PubMed Web of Science ®Google Scholar
• Desmettre T, Devoisselle JM, Mordon S. Fluorescence properties and metabolic features ofindocyanine green (icg) as related to angiography. Surv Ophthalmol 2000;45:15–27
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 2010;197:3–53
   PubMedGoogle Scholar